ISTH 2022 | HAVEN 6: emicizumab prophylaxis in non-severe hemophilia A without FVIII inhibitors
Cédric Hermans, MD, PhD, Catholic University of Louvain, Brussels, Belgium, shares the results of HAVEN 6 (NCT04158648), a Phase III study evaluating emicizumab prophylaxis in patients with mild or moderate hemophilia A without factor VIII (FVIII) inhibitors. Prof. Hermans first describes the characteristics of the patients included in this study and the treatment regimen followed in this trial. Prof. Hermans then moves on to discuss the safety and efficacy profile of this drug, explaining that the study reported no adverse events related to emicizumab or leading to treatment withdrawal, as well as remarkable efficacy across all bleeding endpoints. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.
